Epizyme's investigational new drug application gets FDA nod
Thursday, May 05, 2016
Epizyme announces fda acceptance of investigational new drug application for tazemetostat in mesothelioma.
In q3 of this year, company plans to initiate a phase 2 study in patients with mesothelioma.
Source : reuters.com
